The abstract is read at the publisher; the summary is JClub's.
Ixazomib disrupts SOX2 condensates in HSP70-dependent fashion, dissolving SOX2 AD1 condensates and suppressing condensate-positive squamous cell carcinoma progression in patient-derived xenografts.
- Why it matters: Squamous cell carcinomas are lethal, but SCC-specific therapies are hard to develop because few druggable targets are known.
- What they did: The study used site-specific SOX2 mutagenesis, orthotopic mouse models, multi-omics sequencing, and an FDA-approved drug screen to test how SOX2 condensation and ixazomib affect SOX2 chromatin occupancy and H3K27ac at oncogenic loci.
- The result: SOX2 condensates were linked to higher oncogene expression via increased SOX2 chromatin occupancy, H3K27ac enrichment, and chromatin interactions at loci like FGFR2, and ixazomib selectively downregulated oncogenes and suppressed condensate-positive SCC patient-derived xenografts.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.